A detailed history of E Fund Management Co., Ltd. transactions in Incyte Corp stock. As of the latest transaction made, E Fund Management Co., Ltd. holds 20,240 shares of INCY stock, worth $1.37 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares
20,240
Previous 10,507 92.63%
Holding current value
$1.37 Million
Previous $598,000 105.02%
% of portfolio
0.07%
Previous 0.04%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$51.18 - $63.75 $498,134 - $620,478
9,733 Added 92.63%
20,240 $1.23 Million
Q1 2024

May 13, 2024

SELL
$56.55 - $66.59 $68,142 - $80,240
-1,205 Reduced 10.29%
10,507 $598,000
Q4 2023

Feb 06, 2024

BUY
$52.16 - $64.19 $150,533 - $185,252
2,886 Added 32.7%
11,712 $735,000
Q3 2023

Nov 13, 2023

SELL
$57.77 - $65.93 $19,699 - $22,482
-341 Reduced 3.72%
8,826 $510,000
Q2 2023

Aug 11, 2023

BUY
$60.95 - $75.51 $129,214 - $160,081
2,120 Added 30.08%
9,167 $571,000
Q1 2023

May 11, 2023

BUY
$70.23 - $86.01 $17,206 - $21,072
245 Added 3.6%
7,047 $509,000
Q4 2022

Feb 14, 2023

SELL
$67.18 - $84.11 $132,210 - $165,528
-1,968 Reduced 22.44%
6,802 $546,000
Q3 2022

Nov 14, 2022

BUY
$66.18 - $82.86 $51,818 - $64,879
783 Added 9.8%
8,770 $584,000
Q2 2022

Aug 15, 2022

BUY
$66.18 - $83.18 $167,964 - $211,110
2,538 Added 46.58%
7,987 $607,000
Q1 2022

May 12, 2022

BUY
$66.02 - $79.71 $33,142 - $40,014
502 Added 10.15%
5,449 $433,000
Q4 2021

Feb 11, 2022

SELL
$63.34 - $74.11 $120,282 - $140,734
-1,899 Reduced 27.74%
4,947 $363,000
Q3 2021

Nov 12, 2021

BUY
$68.67 - $84.02 $90,987 - $111,326
1,325 Added 24.0%
6,846 $471,000
Q1 2021

May 12, 2021

BUY
$76.02 - $100.5 $419,706 - $554,860
5,521 New
5,521 $0

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $15B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track E Fund Management Co., Ltd. Portfolio

Follow E Fund Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on E Fund Management Co., Ltd. with notifications on news.